SunCoke Energy, Inc. Announces First Quarter 2018 Earnings Date
Get Alerts SXC Hot Sheet
Join SI Premium – FREE
LISLE, Ill., April 5, 2018 /PRNewswire/ -- SunCoke Energy, Inc. (NYSE: SXC) plans to release its first quarter 2018 financial results on Thursday, April 26, 2018, before trading opens on the New York Stock Exchange.

SXC will host its quarterly earnings call at 11:00 am ET on April 26, 2018. The conference call will be webcast live and archived for replay in the Investors section of www.suncoke.com. Investors may participate in this call by dialing 1-833-236-5757 in the U.S. or 1-647-689-4185 if outside the U.S., confirmation code 2998448.
ABOUT SUNCOKE ENERGY, INC.SunCoke Energy, Inc. (NYSE: SXC) and its sponsored master limited partnership subsidiary, SunCoke Energy Partners, L.P. (NYSE: SXCP), supply high-quality coke used in the blast furnace production of steel, under long-term, take-or-pay contracts that pass through commodity and certain operating costs to customers. We utilize an innovative heat-recovery technology that captures excess heat for steam or electrical power generation. Our cokemaking facilities are located in Illinois, Indiana, Ohio, Virginia, Brazil and India. We have more than 50 years of cokemaking experience serving the integrated steel industry. Through SXCP, we provide export and domestic material handling services to coke, coal, steel, power and other bulk and liquids customers. Our logistics terminals have the collective capacity to blend and transload more than 40 million tons of material each year and are strategically located to reach Gulf Coast, East Coast, Great Lakes and international ports. To learn more about SunCoke Energy, Inc. and SunCoke Energy Partners, L.P., visit our website at www.suncoke.com.
View original content with multimedia:http://www.prnewswire.com/news-releases/suncoke-energy-inc-announces-first-quarter-2018-earnings-date-300624733.html
SOURCE SunCoke Energy, Inc.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Is the global equity rally broadening? UBS weighs in
- Anbogen Therapeutics and The University of Tokyo Enter Collaborative Research Agreement to Evaluate ABT-301 Across Multiple Tumor Types, Targeting Accelerated Human Clinical Indication Expansion
- BofA maintains underperform ratings on six BDC stocks
Create E-mail Alert Related Categories
Press ReleasesRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!



Tweet
Share